Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002578 · ClinicalTrials.gov registry record · Phase 2

Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

A Phase 2 study of Lymphoma, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
3
Study locations

NCT00002578: Completed Phase 2 study of Lymphoma, sponsored by Roswell Park Cancer Institute.

NCT00002578 is a Phase 2 study of Lymphoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 35 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002578, a Phase 2 study of Lymphoma, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma.

Conditions Studied

Lymphoma

Interventions

  • DRUG leucovorin calcium
  • DRUG methotrexate
  • DRUG cytarabine
  • DRUG gallium nitrate

Study Locations (3)

New York

  • Roswell Park Cancer Institute - Buffalo
  • Albert Einstein Comprehensive Cancer Center - The Bronx

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 1994-08
Phase Phase 2
Roswell Park Cancer Institute

365 total trials

What the finished NCT00002578 record still lists

NCT00002578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which leucovorin calcium is the first listed.

NCT00002578 reports a single indexed study location in New York, California.

Frequently Asked Questions

What is clinical trial NCT00002578 about?

NCT00002578 is a clinical study titled "Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma". RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related non-Hodgkin's lymphoma.

What is the current status of trial NCT00002578?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1994-08.

What conditions does trial NCT00002578 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00002578?

The interventions under investigation include: leucovorin calcium (DRUG), methotrexate (DRUG), cytarabine (DRUG), gallium nitrate (DRUG).

Who is sponsoring clinical trial NCT00002578?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002578 being conducted?

This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002578's enrollment target sits among peer trials

35 196th of 299 higher than 98 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00002578, the US trial registry maintained by the National Library of Medicine. NCT00002578 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.